Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
  1. Home
  2. Search

Refine search

Refine search

Access:
Content type:
Publication date:
Apply   From and To filters
Subject: Show more
Journals Show more
Publishers: Show more
Societies Show more
Series: Show more
Collections: Show more

Actions for selected content:

Select all | Deselect all
  • View selected items
  • Export citations
  • Download PDF (zip)
  • Save to Kindle
  • Save to Dropbox
  • Save to Google Drive

Save Search

You can save your searches here and later view and run them again in "My saved searches".

Please provide a title, maximum of 40 characters.
Cancel
×

1 results

  • Chapter 11 - Fetal and Neonatal Alloimmune Thrombocytopenia: Clinical Disease and Management

  • from Red Cell Alloimmunization
  • Edited by Mark D. Kilby, University of Birmingham, Anthony Johnson, Dick Oepkes
  • Book:
    Fetal Therapy
    Published online:
    21 October 2019
    Print publication:
    02 January 2020, pp 99-109

  • Summary

    Fetal and neonatal alloimmune thrombocytopenia (FNAIT) is one of the most important causes of thrombocytopenia in otherwise healthy, term-born infants [1]. During fetal life, the fetal platelet count rapidly increases and reaches a constant normal level, equal to adults, by the end of the first trimester. Therefore, the definition of a normal platelet count and thrombocytopenia in fetuses and neonates is equal to adults. Normal platelet counts range from 150–450 × 109/L and a (fetal or neonatal) platelet count below the 5th percentile, 150×109/L, is defined as thrombocytopenia [2]. Further classification into different degrees of thrombocytopenia can be made into mild (100–150 × 109/L), moderate (50–100 × 109/L), severe (<50 × 109/L), and very severe thrombocytopenia (<20–30 × 109/L).